Tel Aviv-based Kitov Pharmaceuticals (TASE: KTOV) saw its shares plunge 35% to 36.20 shekels pre-marker, before trading was halted, as the company announced that the Israeli Securities Authority has begun a formal investigation into the company’s public disclosures around its lead drug candidate, KIT-302.
J Paul Waymack, chairman of the board and chief medical officer, stated: “Kitov stands fully behind the validity of all of its clinical trial results. The company continues to move forward toward the filing of our New Drug Application for KIT-302 with the FDA.”
The investigation is in its initial stages, and Kitov’s officers are cooperating fully. Kitov’s management looks forward to the conclusion of this investigation in the most expeditious manner possible, the official statement noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze